©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 114415
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.114415
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.114415
Figure 4 Stem cell-based clinical trials for liver diseases.
A: The categories of the registered stem cell-based clinical trials for liver diseases according to ClinicalTrial.gov; B-D: The status, clinical stage and location of the abovementioned stem cell-based clinical trials; E and F: The distribution of stem cell-based clinical trials for liver diseases according to the enrolled participants [enrollment (Log2N21)] and the corresponding cell types (N22) or the clinical trial number [condition (N23)]. BM-EPCs: Bone marrow-derived endothelial progenitor cells; LC: Liver cells; MSCs: Mesenchymal stem/stromal cells; hiPSCs: Human induced pluripotent stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem/stromal cells; UC-MSCs: Umbilical cord-derived mesenchymal stem/stromal cells; ACLF: Acute-on-chronic liver failure; NASH: Non-alcoholic steatohepatitis.
- Citation: Wang YX, Ren YN, Zhang SS, Sun S, Xu MY, Wei T, Zhang LS. Application of stem cells in the precise diagnosis and treatment of liver diseases. World J Gastroenterol 2025; 31(46): 114415
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/114415.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.114415